# Research Pulse — 2026-08-18 _Generated 2026-08-18 07:33 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 8월 18일 (화요일) · Converging(통합 Day)** 8/18(통합)→8/17(Standardizing)→8/16(Industrializing)→8/15(Sustaining)→8/14(Accelerating)→8/13(Catalyzing)→8/12(Consolidating)→8/11(Integrating)→...→7/14(가속). Standardizing(8/17)된 기술들이 **이종 기술 간 통합(Converging)으로 다음 단계 파괴적 혁신의 조건을 충족하는 날** — VLP CRISPR-RNP platform이 genome editing + epigenome silencing 통합 전달 체계로 확립(Ju Molecular Therapy 2026), AI-pharma partnership이 relational dynamics + IP governance 체계로 partnership effectiveness 분석(Kint Drug Discovery Today 2024), de novo protein design 이행 장벽 분석 + programmable functions 설계의 현재 상태 동시 확립(Gao Journal Translational Medicine 2026 + Kortemme Cell 2024), SCMBench로 FM vs DM 성능 격차 실증 + lightweight adaptation bridging(Wang Nature Communications 2026), FDA CGT 38개 승인에서 expedited pathway + surrogate endpoints 의존 구조 + AI/ML analytics 적용 확대 동시 확인(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026), spatial transcriptomics 5개 플랫폼 FFPE benchmark 체계 확립(Cervilla Genome Biology 2026)이 동시에 진행된다. Converging은 Standardizing의 다음 단계다. 오늘 6개 전선은 표준화된 기술들이 **이종 기술 간 통합으로 파괴적 혁신의 조건을 충족하는 날**이다. *출처: [Ju VLP CRISPR RNP Platform Molecular Therapy 2026](https://consensus.app/papers/details/15d0eb81b9d65679bd6ad93b0c8b5fe6/), [Kint AI-Pharma Partnership Drug Discovery Today 2024](https://consensus.app/papers/details/d511aace344b5cfa8a5718fbe05636b8/), [Gao De Novo Protein Clinical Translation Journal Translational Medicine 2026](https://consensus.app/papers/details/a2d9b38918ca58068cd14b2e81a77510/), [Kortemme De Novo Protein Design Cell 2024](https://consensus.app/papers/details/8f1a29cdc95f5d7485cd8ace90547085/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)* *#ConvergingDay #VLP #CRISPRRNP #MolecularTherapy #Ju #GenomeEditing #EpigenomeSilencing #Kint #Partnership #IPGovernance #Gao #DeNovoProtein #ClinicalTranslation #Kortemme #ProgrammableFunctions #Wang #SCMBench #FoundationModel #FMvsDM #LightweightAdaptation #Oo #FDA #CGT #ExpeditedPathway #SurrogateEndpoints #Cervilla #SpatialTranscriptomics #Benchmark #FFPE #PlatformComparison* --- ### Post 2: CRISPR & Gene Editing — VLP CRISPR-RNP 통합 플랫폼과 Non-Viral Delivery 산업화 🧪 **[CRISPR/Gene Editing] VLP CRISPR-RNP platform이 genome editing + epigenome silencing 통합 전달 체계로 확립(Ju Molecular Therapy 2026) + Targeted nonviral delivery of genome editors가 in vivo genome editing therapy의 다음 breakthrough로 확인(Tsuchida PNAS 2024) + CRISPRoff + VLP 통합으로 120일 stable gene silencing 달성 확인: 이종 전달 기술 통합(Converging) 확인** 유전자 편집 전달 기술의**이종 통합**이 출처에서 동시에 확인된다[1][2]. **VLP CRISPR-RNP: Genome + Epigenome 통합 플랫폼[1]** Sungjin Ju et al.(Molecular Therapy 2026)의 연구는 VLP CRISPR-RNP platform을 제시한다. **Transient DNA-free delivery**: 지속 노출 없음, off-target activity 낮음, efficiency 높음, hepatotoxicity 없음(in vivo safety profile 확인). **Genome editing + epigenome silencing 통합**: CRISPRoff(표현 억제)로 120일 이상 stable gene silencing 유지. oncogenic alleles mutation-selective targeting으로 종양 성장 억제 확인. **Knockout escape 극복**: conventional genome editing의 key limitation 극복. **산업화적 우위**: streamlined manufacturing capability + transient expression profile. 핵심: VLP CRISPR-RNP platform으로 genome + epigenome 통합 전달 체계 확립 — 제조-안전성 통합. **Nonviral Delivery: In Vivo Genome Editing Therapy의 다음 Breakthrough[2]** Connor A. Tsuchida et al.(PNAS 2024)의 review는 nonviral delivery of genome editors를 분석한다. **Cell-type-specific in vivo delivery of genome editing molecules**: 다음 breakthrough로 확립. **Preassembled ribonucleoproteins(RNPs) 또는 mRNA encoded delivery** 두 전략 모두 viral vector-mediated delivery의 pitfalls 극복. **우위**: transient editor lifetime + streamlined manufacturing capability. **Clinical use에서 이미 가치 입증**: transient nature가 low frequencies of off-target events + minimized window of immune activation. 핵심: Nonviral delivery가 in vivo genome editing therapy의 다음 breakthrough로 확립 — CRISPRoff(120일 stable silencing)와의 통합으로 산업화 속도 가속. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 VLP CRISPR-RNP + non-viral nanoparticles CAR-T의 **산업화 체계**를 제시했다면, 오늘은 **Ju Molecular Therapy**으로 **VLP CRISPR-RNP의 genome + epigenome silencing 통합 플랫폼**을(두 기술의 convergent 통합), **Tsuchida PNAS**으로 **nonviral delivery의 다음 breakthrough 지위 확립**을(파괴적 혁신 조건 충족) 동시에 제시한다. Standardizing(8/17) → 이종 기술 통합 Converging(8/18). 실무 함의: 유전자 치료 전달 기술팀에서 Ju et al.의 VLP CRISPRoff 통합 플랫폼을 분석하여 genome + epigenome convergence 전략을 수립해야 한다. *출처: [Ju VLP CRISPR RNP Platform Molecular Therapy 2026](https://consensus.app/papers/details/15d0eb81b9d65679bd6ad93b0c8b5fe6/), [Tsuchida Targeted Nonviral Delivery PNAS 2024](https://consensus.app/papers/details/98f0e8783ff75a6696a223e09211df09/)* *#CRISPR #GeneEditing #VLP #Ju #MolecularTherapy #CRISPRoff #EpigenomeSilencing #Tsuchida #PNAS #Nonviral #Delivery #RNP #mRNA #InVivo #Transient #Manufacturing #120Day #Silencing #KnockoutEscape #ConvergingDay #Integration #GenomeEditing #Safety* --- ### Post 3: AI 신약 — AI-Pharma Partnership Relational Dynamics와 Partnership Effectiveness 💊 **[AI 신약] AI-pharma partnerships의 relational dynamics 연구로 partnership effectiveness의 핵심 요인 분석 확인(Kint Drug Discovery Today 2024) + AI-driven drug discovery의 산업 적용 현황과 전망 종합 확인(Chen Fu Journal Pharmaceutical Analysis 2025): partnership governance 체계 분석** AI-Driven Drug Discovery의**partnership governance 체계**가 출처에서 동시에 확인된다[3][4]. **AI-Pharma Partnership: Relational Dynamics와 Partnership Effectiveness[3]** Stefan Kint et al.(Drug Discovery Today 2024)의 연구는 AI-driven drug discovery companies(AIDD)와 pharma firms 사이의 partnership을 분석한다. **AIDD companies의 transformative potential**: pharmaceutical development 변환 가능하나 established pharma firms와의 partnership management 방법 미확보. **4가지 key relational aspects**: (1) complementary capabilities 식별, (2) effective governance mechanisms 수립, (3) relationship-specific assets 창출, (4) interfirm knowledge-sharing routines 개발. **IP governance가 partnership success에 essential** 확인. actionable recommendations 제공. 핵심: AI-pharma partnership의 relational dynamics 분석 — partnership effectiveness의 핵심 요인 확립. **AI Drug Discovery & Development: 2025 산업 적용 현황과 전망[4]** Chen Fu et al.(Journal Pharmaceutical Analysis 2025)의 review는 AI-driven drug discovery의 현재 상태를 종합한다. **AI가 drug discovery transformation**: data, computational power, algorithms 통합으로 efficiency, accuracy, success rates 향상, development timelines 단축, costs 절감. **적용 영역**: drug characterization, target discovery and validation, small molecule drug design, clinical trials acceleration. **AI의 molecular generation**: novel drug molecules 생성, properties/activities 예측, virtual screening 최적화. **Challenges**: data-sharing mechanisms 필요, IP protections 필요, wet/dry laboratory experiments fusion 필요. 핵심: AI-driven drug discovery 2025 산업 적용 현황 종합 — transformation potential과 challenges 동시 확인. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 AI-pharma partnership의 **partnership dynamics 분석**을 제시했다면, 오늘은 **Kint Drug Discovery Today**으로 **4가지 key relational aspects + IP governance의 essential 역할**을(구체적 partnership governance 체계), **Chen Fu Journal Pharmaceutical Analysis**으로 **AI drug discovery 2025 transformation potential과 challenges**를(현실적 적용 체계) 동시에 제시한다. Standardizing(8/17) → partnership governance 체계 분석 + transformation/challenges 동시 확인 Converging(8/18). 실무 함의: AI drug discovery 협업팀에서 Kint et al.의 partnership governance 권고안을 참조하여 collaboration strategy를 수립해야 한다. *출처: [Kint AI-Pharma Partnership Relational Dynamics Drug Discovery Today 2024](https://consensus.app/papers/details/d511aace344b5cfa8a5718fbe05636b8/), [Chen Fu AI Drug Discovery Development Journal Pharmaceutical Analysis 2025](https://consensus.app/papers/details/1308c134b9165903b7d81c4b8c636084/)* *#AI #DrugDiscovery #Kint #DrugDiscoveryToday #Partnership #RelationalDynamics #IPGovernance #ChenFu #JournalPharmaceuticalAnalysis #AIIntegration #Pharma #Collaboration #ConvergingDay #Transformation #VirtualScreening #DeNovo #MolecularGeneration #TargetDiscovery #ClinicalTrials #Manufacturing* --- ### Post 4: 단백질 AI — De Novo Protein Design 이행 장벽 분석과 Programmable Functions 설계 🔬 **[단백질 AI] De novo protein design의 임상 이행 장벽 체계적 분석 + 이행 경로 제시 확인(Gao Journal Translational Medicine 2026) + Kortemme de novo protein design perspective로 programmable functions 설계의 현재 상태와 전망 종합(Kortemme Cell 2024): de novo protein design의 convergence 동시 확인** 단백질 AI의**이행 장벽 분석과 programmable functions convergence**가 출처에서 동시에 확인된다[5][6]. **De Novo Protein Design Clinical Translation: 이행 장벽 분석과 경로 제시[5]** Jie Gao et al.(Journal Translational Medicine 2026)의 review는 de novo protein design의 임상 적용 장벽을 체계적으로 분석한다. **배경**: protein biologics가 질병 예방·진단·치료에 필수적이나 native protein scaffolds 의존으로 제약 — long development timelines, limited structural/functional tunability, manufacturing consistency challenges, high production costs. **De novo protein design의 우위**: tailor-made structures and functions 직접 생성. **현재 장벽**: biological, technical, translational considerations — 임상 적용에 다방면 장벽 존재. **이행 경로**: computational design + experimental validation + engineering optimization + clinical needs의 closer coordination 필요. clinical feasibility를 early-stage에서 고려해야 함. 핵심: De novo protein design의 임상 이행 장벽 체계적 분석 + 이행 경로 제시 — convergence 조건 충족. **De Novo Protein Design: Programmable Functions 설계의 현재 상태[6]** Tanja Kortemme(Cell 2024)의 perspective는 de novo protein design의 현재 상태를 종합한다. **AI trained on large datasets**: proteins with new shapes and molecular functions de novo 설계 가능. **접근 방식**: physics-based modeling + AI combination. **성공 영역**: new protein folds, higher-order assemblies 설계 가능. **향후 방향**: catalysts for high energy barrier reactions, switches and nanomachines(변형, 결합, 촉매 통합). **합성 세포 신호 경로 구축** 가능성. 핵심: De novo protein design의 programmable functions 설계 현재 상태 — future frontiers 제시. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 de novo protein design의 **이행 장벽 체계적 분석**을 제시했다면, 오늘은 **Gao Journal Translational Medicine**으로 **이행 장벽 + 이행 경로**를(실용화 convergence), **Kortemme Cell**으로 **programmable functions 설계의 현재 상태 + future frontiers**를(설계-기능 convergence) 동시에 제시한다. Standardizing(8/17) → 이행 장벽 분석 + programmable functions convergence Converging(8/18). 실무 함의: 단백질 설계팀에서 Gao et al.의 이행 장벽 분석을 참조하여 clinical translation roadmap을 수립해야 한다. *출처: [Gao De Novo Protein Design Clinical Translation Journal Translational Medicine 2026](https://consensus.app/papers/details/a2d9b38918ca58068cd14b2e81a77510/), [Kortemme De Novo Protein Design Programmable Functions Cell 2024](https://consensus.app/papers/details/8f1a29cdc95f5d7485cd8ace90547085/)* *#ProteinAI #DeNovoProteinDesign #Gao #JournalTranslationalMedicine #ClinicalTranslation #Barriers #Kortemme #Cell2024 #ProgrammableFunctions #Catalysts #Nanomachines #ConvergingDay #Manufacturing #ClinicalFeasibility #ProteinEngineering #MolecularDesign #AI #DeepLearning #PhysicsBased #FutureFrontiers* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — SCMBench Benchmark 체계와 Foundation Model Convergence 🬬 **[Single-Cell Multi-Omics Foundation Model] SCMBench로 foundation models(FMs) vs domain-specific models(DMs) 성능 격차 실증 + lightweight adaptation strategy로 bridging 확인(Wang Nature Communications 2026) + scGPT foundation model의 cross-species annotation + perturbation prediction 확인(Cui Nature Methods 2024): foundation model의 convergence 체계 동시 확인** Single-Cell Foundation Model의**convergence 체계**가 출처에서 동시에 확인된다[7][8]. **SCMBench: FM vs DM 성능 격차 실증 + Lightweight Adaptation[7]** Yixuan Wang et al.(Nature Communications 2026)의 연구는 SCMBenchmark로 single-cell multi-omics integration을 평가한다. **23 methods 평가** — integration accuracy, biomarker detection, trajectory inference, batch effect correction. **FMs이 state-of-the-art DMs에 미치지 못함 확인** — 그러나 **lightweight adaptation strategy로 performance gap bridging** 가능. **핵심 industrialization 메시지**: foundation models의 현재 한계 인식 + lightweight adaptation으로 실전 적용 가능. 핵심: SCMBench로 FM vs DM 성능 격차 실증 + lightweight adaptation bridging — convergence 조건 충족. **scGPT: Cross-Species + Perturbation Prediction의 산업 적용[8]** Haotian Cui et al.(Nature Methods 2024)의 연구는 scGPT foundation model을 제시한다. **33 million+ cellsRepository로 훈련된 generative pretrained transformer** — cross-species cell type annotation + perturbation response prediction + gene network inference에서 transfer learning 적용. **산업 적용 시사점**: cell type annotation, multi-batch integration, multi-omic integration, perturbation prediction, gene network inference에서 superior performance. Multi-omics integration의 산업 표준 도구로 적용 가능. 핵심: scGPT foundation model로 cross-species + perturbation prediction 산업 적용 — foundation model의 실전 convergence 확인. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 **Wang Nature Communications**으로 **SCMBench FM vs DM 성능 격차 + lightweight adaptation**을 제시했다면, 오늘은 **Wang SCMBench**으로 **이종 integration task convergence**를(평가 체계 convergence), **Cui scGPT**으로 **cross-species + perturbation prediction convergence**를(적용 체계 convergence) 동시에 제시한다. Standardizing(8/17) → 평가 체계 + 적용 체계 convergence Converging(8/18). 실무 함의: 단일세포 연구팀에서 Wang et al.의 SCMBench 결과를 분석하여 foundation model convergence strategy를 수립해야 한다. *출처: [Wang SCMBench Foundation Models Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cui scGPT Foundation Model Nature Methods 2024](https://consensus.app/papers/details/e981363edc3158d0a0714216da031ed5/)* *#SingleCell #FoundationModel #SCMBench #Wang #NatureCommunications #FMvsDM #LightweightAdaptation #Bridging #Cui #scGPT #NatureMethods #CrossSpecies #Perturbation #Annotation #ConvergingDay #CellType #MultiOmics #Integration #ClinicalTranslation #Benchmarking #Standardization* --- ### Post 6: FDA/규제 — CGT 38개 승인 분석과 AI/ML Analytics 규제 적용 확대 📋 **[FDA/규제] FDA CGT 38개 승인 분석에서 expedited pathway 92.1%/surrogate endpoints 44.7% 의존 + limited premarket data 문제 확인(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026) + AI/ML analytics가 dose selection, safety evaluation, durability prediction 지원 확대 확인(Oo J Clinical Pharmacology 2026): 규제 convergence 체계 분석** FDA/규제의**convergence 체계 분석**이 출처에서 동시에 확인된다[9][10]. **CGT 38개 승인 분석: Expedited Pathway와 Limited Premarket Data 문제[9][10]** C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals를 통합 분석한다[9]. **38개 CGT 분석 결과**: 86.8% orphan designation, 92.1% expedited pathway 사용, 44.7% surrogate endpoints exclusively 의존. **73.4%** postmarketing requirements/commitments 보유. **17.9%만** primary clinical efficacy endpoint 포함. FDA가 platform-aligned initiatives 도입: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **AI/ML analytics**가 dose selection, safety evaluation, durability prediction 지원 확대. **핵심 convergence**: expedited pathway + AI/ML analytics convergence으로 규제-기술 통합 체계 형성. Mahnum Shahzad et al.(Clinical Pharmacology and Therapeutics 2026)의 연구는 FDA CGT 승인을 추가 분석한다[11]. **Current regulatory approaches**: timely access 우선, limited premarket data + postmarketing studies infrequently assess clinical efficacy문제 확인. **AICME/NIPE 경향**: surrogate endpoints exclusively reliance. 핵심: FDA CGT 38개 승인 분석으로 expedited pathway 의존 + limited premarket data 문제 확인 + AI/ML analytics 적용 확대 — 규제 convergence 체계 분석. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 **Oo + Shahzad Clinical Pharmacology**으로 **CGT 38개 승인의 규제 체계 양면성**을 제시했다면, 오늘은 **Oo J Clinical Pharmacology**으로 **AI/ML analytics의 dose selection + safety evaluation + durability prediction 적용 확대**를(규제-기술 convergence), **Shahzad Clinical Pharmacology**으로 **surrogate endpoints exclusively reliance의 문제**를(규제 convergence의 장벽) 동시에 제시한다. Standardizing(8/17) → 규제-기술 convergence + 규제 convergence의 장벽 동시 분석 Converging(8/18). 실무 함의: 규제 기획팀에서 Oo et al.의 분석을 참조하여 AI/ML-integrated regulatory strategy를 수립해야 한다. *출처: [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Approval Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)* *#FDA #GeneTherapy #CGT #Oo #JClinicalPharmacology #Shahzad #ClinicalPharmacology #ExpeditedPathway #SurrogateEndpoints #OrphanDesignation #Postmarketing #AI #ML #Analytics #CMC #Manufacturing #ConvergingDay #TimelyAccess #LimitedData #Durability #Safety #DoseSelection* --- ### Post 7: Spatial Transcriptomics — 5개 플랫폼 Benchmark 체계 확립과 FFPE 임상 샘플 Standardization 🗺️ **[Spatial Transcriptomics] Spatial transcriptomics 6개 암종 5개 플랫폼(Visium v1/v2/CytAssist/Visium HD/Xenium/CosMx) 체계적 비교로 FFPE 임상 샘플 표준 benchmarking 체계 확립(Cervilla Genome Biology 2026) + platform comparison으로 산업 표준 benchmark 체계 동시 확립: spatial transcriptomics의 convergence 체계 확립** Spatial transcriptomics의**convergence 체계 확립**이 Cervilla et al.(Genome Biology 2026)에서 확인된다[11]. **Spatial Transcriptomics 5개 플랫폼 Benchmark: FFPE 임상 샘플 Standardization 체계 확립[11]** Sergi Cervilla et al.(Genome Biology 2026)의 연구는 6개 암종 FFPE 임상 샘플에서 5개 commercial ST 플랫폼(Visium v1, Visium v2/CytAssist, Visium HD, Xenium, CosMx)을 체계적으로 비교한다. **Sequencing-based + imaging-based platforms same samples에서 직접 비교** — modality 간 기술적 비교 최초. **평가 영역**: transcript and UMI detection, gene-histology concordance, cell type recovery, targeted protein panel integration. **독특한 기여**: Xenium Multi-Tissue(377 genes) vs Xenium Prime(5,000 genes) same-sample 비교 — transcript recovery와 spatial signal의 주요 차이 확인. **Visium targeted protein data + matched RNA profiles 통합**: RNA-protein decoupling + spatial heterogeneity in concordance 확인. **핵심 convergence 메시지**: 5개 플랫폼 benchmark 체계 확립으로 spatial transcriptomics의 기술 convergence 체계 형성. Visium CytAssist가 Visium보다 superior data quality, Xenium이 imaging-based platforms 중 더 reliable results, VisiumHD가 subcellular resolution + whole-transcriptome coverage의 양호한 균형 확인. **8월 17일 Standardizing Day vs 오늘의 차별점**: 8/17이 **Cervilla Genome Biology**으로 **5개 플랫폼 benchmark 체계**를 제시했다면, 오늘은 같은 연구에서 **Visium CytAssist vs Visium manual superiority**, **Xenium vs CosMx reliability 차이**, **VisiumHD의 양호한 균형**을(구체적 convergence 체계)를 추가로 제시한다. Standardizing(8/17) → benchmark 체계 + 구체적 convergence 체계 Converging(8/18). 실무 함의: spatial transcriptomics 연구팀에서 Cervilla et al.의 benchmark 결과를 참조하여 플랫폼 convergence strategy를 수립해야 한다. *출처: [Cervilla Spatial Transcriptomics Platform Comparison Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)* *#SpatialTranscriptomics #Cervilla #GenomeBiology #Benchmark #5Platforms #Visium #Xenium #CosMx #FFPE #ClinicalSamples #6CancerTypes #RNAProtein #Decoupling #SpatialHeterogeneity #ConvergingDay #Standardization #CellTypeRecovery #GeneHistology #Sampling #TradeOffs #TechnicalBenchmarking* --- ### Post 8: 오늘의 요약 — Converging(통합 Day) 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 8/18(Converging)의 핵심: Standardizing(8/17)된 기술들이 **이종 기술 간 통합(Converging)으로 다음 단계 파괴적 혁신의 조건을 충족**하는 날이었다. **1. VLP CRISPR-RNP + CRISPRoff 통합 플랫폼(Ju Molecular Therapy 2026)**: genome editing + epigenome silencing 통합 전달 체계 확립 + 120일 stable gene silencing 달성 — genome + epigenome convergence. [Ju Molecular Therapy 2026] **2. Nonviral Delivery의 다음 Breakthrough 지위(Tsuchida PNAS 2024)**: transient editor lifetime + streamlined manufacturing capability으로 in vivo genome editing therapy의 breakthrough 확립 — nonviral convergence. [Tsuchida PNAS 2024] **3. AI-Pharma Partnership 4가지 Key Relational Aspects(Kint Drug Discovery Today 2024)**: complementary capabilities + governance mechanisms + relationship-specific assets + knowledge-sharing routines으로 partnership convergence. [Kint Drug Discovery Today 2024] **4. De Novo Protein Design 이행 장벽 분석 + Programmable Functions(Gao Journal Translational Medicine 2026 + Kortemme Cell 2024)**: 이행 장벽 체계적 분석 + programmable functions 설계 convergence — 실용화-설계 convergence. [Gao Journal Translational Medicine 2026; Kortemme Cell 2024] **5. SCMBench FM vs DM 격차 + Lightweight Adaptation(Wang Nature Communications 2026)**: 23 methods 평가에서 FMs < DMs 확인 + lightweight adaptation으로 bridging — foundation model convergence. [Wang Nature Communications 2026] **6. FDA CGT 38개 승인 + AI/ML Analytics 규제 적용 확대(Oo J Clinical Pharmacology 2026 + Shahzad Clinical Pharmacology 2026)**: expedited pathway 92.1% + surrogate endpoints 44.7% + AI/ML analytics convergence — 규제-기술 convergence. [Oo J Clinical Pharmacology 2026] **8월 19일 전망**: Converging된 기술들의 이종 통합 속도가 핵심 변수. 특히 VLP CRISPRoff 통합 플랫폼의 임상 적용, AI/ML-integrated regulatory framework의 구체화, spatial transcriptomics 플랫폼 convergence 체계의 임상采纳이 관전. *출처: [Ju VLP CRISPR RNP Molecular Therapy 2026](https://consensus.app/papers/details/15d0eb81b9d65679bd6ad93b0c8b5fe6/), [Tsuchida Nonviral Delivery PNAS 2024](https://consensus.app/papers/details/98f0e8783ff75a6696a223e09211df09/), [Kint AI-Pharma Partnership Drug Discovery Today 2024](https://consensus.app/papers/details/d511aace344b5cfa8a5718fbe05636b8/), [Chen Fu AI Drug Discovery Journal Pharmaceutical Analysis 2025](https://consensus.app/papers/details/1308c134b9165903b7d81c4b8c636084/), [Gao De Novo Protein Clinical Translation Journal Translational Medicine 2026](https://consensus.app/papers/details/a2d9b38918ca58068cd14b2e81a77510/), [Kortemme De Novo Protein Design Cell 2024](https://consensus.app/papers/details/8f1a29cdc95f5d7485cd8ace90547085/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)* *#ConvergingDay #Summary #Ju #VLP #CRISPRRNP #CRISPRoff #MolecularTherapy #Tsuchida #PNAS #Nonviral #Kint #Partnership #IPGovernance #Gao #DeNovoProtein #Kortemme #ProgrammableFunctions #Wang #SCMBench #FoundationModel #Oo #FDA #CGT #AI #ML #Analytics #Converging #Integration #Standardization #Manufacturing #ClinicalTranslation* --- ## Sources [1] [Ju et al. — A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer. Molecular Therapy 2026](https://consensus.app/papers/details/15d0eb81b9d65679bd6ad93b0c8b5fe6/) [2] [Tsuchida et al. — Targeted nonviral delivery of genome editors in vivo. PNAS 2024](https://consensus.app/papers/details/98f0e8783ff75a6696a223e09211df09/) [3] [Kint et al. — Strategic partnerships for AI-driven drug discovery: The role of relational dynamics. Drug Discovery Today 2024](https://consensus.app/papers/details/d511aace344b5cfa8a5718fbe05636b8/) [4] [Chen Fu et al. — The future of pharmaceuticals: Artificial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis 2025](https://consensus.app/papers/details/1308c134b9165903b7d81c4b8c636084/) [5] [Gao et al. — De novo protein design: a transformative frontier in clinical protein applications. Journal of Translational Medicine 2026](https://consensus.app/papers/details/a2d9b38918ca58068cd14b2e81a77510/) [6] [Kortemme — De novo protein design – from new structures to programmable functions. Cell 2024](https://consensus.app/papers/details/8f1a29cdc95f5d7485cd8ace90547085/) [7] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [8] [Cui et al. — scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nature Methods 2024](https://consensus.app/papers/details/e981363edc3158d0a0714216da031ed5/) [9] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [10] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology and Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/) [11] [Cervilla et al. — A technical comparison of spatial transcriptomics platforms across six cancer types. Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)
Research Pulse·2026-08-18
Research Pulse — 2026-08-18
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief